论文部分内容阅读
目的探讨急性冠状动脉综合征(ACS)患者采用阿托伐他汀治疗的效果与药理解析。方法 78例ACS患者,随机分为对照组和治疗组,各39例。对照组接受常规综合疗法,治疗组在常规综合疗法基础上增加阿托伐他汀治疗,对比两组患者血脂达标率和治疗前后的C反应蛋白水平变化。结果治疗组患者的血脂达标率为94.9%,对照组患者的血脂达标率为74.4%,两组患者血脂达标率比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者的C反应蛋白水平为(3.2±0.7)mg/L优于对照组的(5.3±1.2)mg/L,比较差异具有统计学意义(P<0.05)。结论 ACS患者采用阿托伐他汀治疗的临床效果确切,且可明显提升其血脂达标率,改善其C反应蛋白水平。
Objective To investigate the effect and pharmacological analysis of atorvastatin in patients with acute coronary syndrome (ACS). Methods 78 ACS patients were randomly divided into control group and treatment group, 39 cases in each. The control group received conventional combination therapy. The treatment group was given atorvastatin on the basis of conventional combination therapy. The blood lipid compliance rate and C-reactive protein level before and after treatment were compared between the two groups. Results The blood lipid compliance rate was 94.9% in the treatment group and 74.4% in the control group. There was significant difference between the two groups in the blood lipid compliance rate (P <0.05). After treatment, the level of C-reactive protein in the treatment group was (3.2 ± 0.7) mg / L better than that in the control group (5.3 ± 1.2) mg / L, with statistical significance (P <0.05). Conclusion The clinical effect of atorvastatin treatment in patients with ACS is exact, and can significantly improve the compliance rate of lipid and improve the C-reactive protein level.